Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;208(3):221.e1-8.
doi: 10.1016/j.ajog.2012.12.023. Epub 2012 Dec 16.

Safety of macrolides during pregnancy

Kueiyu Joshua Lin  1 , Allen A Mitchell, Wai-Ping Yau, Carol Louik, Sonia Hernández-Díaz
Affiliations

Safety of macrolides during pregnancy

Kueiyu Joshua Lin et al. Am J Obstet Gynecol. 2013 Mar.

Abstract

Objective: Prior studies have reported increased risks of congenital heart defects (CHD) and pyloric stenosis (PS) after prenatal exposure to macrolide antibiotics. We sought to assess the association between maternal use of erythromycin and nonerythromycin macrolides and the risks of CHD and PS.

Study design: Among participants in the Slone Epidemiology Center Birth Defects Study from 1994 through 2008, we identified 4132 infants with CHD and 735 with PS as cases, and 6952 infants without any malformation as controls. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) associated with use of erythromycin or nonerythromycin macrolides in each trimester using conditional logistic regression and adjusting for risk factors for CHD and PS, fever, specific types of infections, and their associated treatments.

Results: During the first trimester, 0.4% and 0.7% of control women had used erythromycin and nonerythromycin macrolides, respectively. Compared to non-use during pregnancy, first-trimester exposure to erythromycin was not associated with an increased risk of CHD (OR, 1.3; 95% CI, 0.6-2.6) or PS (OR, 0.9; 95% CI, 0.3-3.0). The corresponding ORs for nonerythromycin macrolides were 0.7 (95% CI, 0.4-1.3) for CHD and 1.7 (95% CI, 0.6-4.6) for PS. We found no association between third-trimester exposure to erythromycin or nonerythromycin macrolides and the risk of PS. Hypothesis generation analyses did not identify appreciable associations between maternal use of macrolides and other common specific birth defects.

Conclusion: We found no meaningful associations between the risks of CHD, PS, and other common malformations in relation to use of macrolides in pregnancy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest:

The authors report no conflict of interest.

Figures

Figure 1
Figure 1. Prevalence of antibiotic use in the first trimester by calendar years of mothers’ last menstrual period date
Note:

  1. The figure presents trends for those study centers that contribute data throughout study period, i.e., Boston and Philadelphia area.

  2. Note: 4.1% of women reported having used an antibiotic but the type could not be specified.

See this image and copyright information in PMC

References

    1. 1998 guidelines for treatment of sexually transmitted diseases. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47:1–111. - PubMed
    1. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernandez-Diaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. 2011;205:51, e1–8. - PMC - PubMed
    1. Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 2009;163:978–85. - PubMed
    1. Klein JO. History of macrolide use in pediatrics. Pediatr Infect Dis J. 1997;16:427–31. - PubMed
    1. Kallen BA, Otterblad Olausson P, Danielsson BR. Is erythromycin therapy teratogenic in humans? Reprod Toxicol. 2005;20:209–14. - PubMed

Publication types